




**Embrace Changes and Prevent Overdose:
A Basic Blueprint for Legal Risk Mitigation and Response**

Created and presented by:
Jennifer Bolen, JD
PainWeek and PainWeekEnd 2019



3/28/19

**Disclosures for Jennifer Bolen,
JD (as of 03/01/2019)**



• Consultant: Paradigm Labs

3/28/19

Course Objectives

Identify

- Identify common trends in legal actions against opioid prescribers.

List and Describe

- List three common weaknesses associated with documentation of risk assessment of patients for chronic opioid therapy, and describe how they can contribute to bad legal outcomes.


Explain

- Explain how to create a risk evaluation action plan and supporting documentation.


3/28/19

OBJECTIVE 1:

Identify common trends in legal actions against opioid prescribers.



3/1/19




Department of Justice
U.S. Attorney Office
Eastern District of Virginia

FOR IMMEDIATE RELEASE

U.S. Attorney Issues Warnings for Hybrid Prescribers

3/3/19



Department of Justice
U.S. Attorney Office
Middle District of Florida

FOR IMMEDIATE RELEASE


Chemist Doctor Sentenced to Prison For Health Care Fraud

3/3/19


Legitimate Medical Purpose <ul style="list-style-type: none">• One or more generally recognized medical indication for the use of the controlled substance	Usual Course of Professional Practice <ul style="list-style-type: none">• According to licensing and professional standards, including consideration of licensing board material;• Steps of a "Reasonably Prudent" Practitioner	Reasonable Steps to Prevent Abuse and Diversion <ul style="list-style-type: none">• Proper Risk Evaluation, Stratification, and Monitoring Protocols, including overdose risk evaluation• PDMP, UDT, NALOXONE, OPIOID TRIAL, VISIT FREQUENCY• Many other "reasonable steps"
<p>DEA "Standards" for Registrants who Prescribe Controlled Substances <small>3/2/19</small></p>		

POSITION OF TRUST

Reminder:
Core Responsibilities when Prescribing Controlled Substances



3/2/19



State Overview —

- ARIZONA
- CALIFORNIA
- COLORADO
- TEXAS

3/2/19

INSERT STATE UPDATES FOR EACH LOCATION

- STATE-SPECIFIC SLIDES WILL BE INSERTED FOLLOWING RESEARCH JUST PRIOR TO THE PRESENTATION.
- THIS KEEPS THE MATERIAL CURRENT FOR ATTENDEES.
- BOLEN WILL UPLOAD USEFUL HANDOUTS AND CITE LINKS.
- ADDENDUM: I REMOVED HEAVY GRAPHICS (PDF CLIPS) FROM THIS SECTION TO REDUCE SIZE OF FILE. NONE REFERENCED ANY COMPANY OR MEDICATION BRAND. ALL LICENSING BOARD RELATED.

3/2/19

OBJECTIVE 2:

List three common weaknesses associated with documentation of risk assessment of patients for chronic opioid therapy, and describe how they can contribute to bad legal outcomes.



3/2/19

LEGAL PERSPECTIVE:

Three common risk mitigation weaknesses – chronic opioid therapy

- 1 • Poor Risk Assessment Process and Follow Through.
- 2 • Untimely Use of Information gathered through Risk Assessment/Evaluation and Patient Encounters.
- 3 • Failure to Coordinate Care with Other Healthcare Providers and Lack of Patient Education Related to Coordination of Care Issues.

3/2/19

CDC Says Risk Assessment is . . .
https://www.cdc.gov/drugoverdose/pdf/Guidelines_Factsheet-a.pdf

ASSESSING RISK AND ADDRESSING HARMS OF OPIOID USE

8 Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-related harms. Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages (≥50 MME/day), or concurrent benzodiazepine use, are present.

9 Clinicians should review the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP) data to determine whether the patient is receiving opioid dosages or excessive combinations that put him or her at high risk for overdose. Clinicians should review PDMP data when starting opioid therapy for chronic pain and periodically during opioid therapy for chronic pain, ranging from every prescription to every 3 months.

10 When prescribing opioids for chronic pain, clinicians should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs.


11 Clinicians should avoid prescribing opioid pain medication and benzodiazepines concurrently whenever possible.

CLINICAL REMINDERS


- Evaluate risk factors for opioid-related harms
- Check PDMP for high dosages and prescribers from other providers
- Use urine drug testing to identify prescribed substances and undisclosed use
- Avoid concurrent benzodiazepine and opioid prescribing
- Arrange treatment for opioid use disorder if needed


3/3/19


American Academy of Pain Medicine Says Risk Assessment is . . .




American Academy of Pain Medicine Says Risk Factors of Opioid Misuse and Opioid Use Disorder Include . . .









Legal Perspective on Commonly Referenced Medical Co-Morbidities that Enhance Risk of Overdose Event

Respiratory Co-Morbidities (Asthma, COPD, Sleep Apnea)

Hepatic Insufficiencies

Renal Insufficiencies

Other

3/2/19

Legal Perspective: Commonly Referenced Psycho-Social Factors and Risk

Behavioral Health History

Aberrant, Drug Related Behaviors (PDMP-Doctor-shopping, Discharge for self-escalation, other behaviors tied to patient's relationship with prescription drugs and other substances)

Smoking, Drinking - Personal and First Degree Relative History; Substance Use Disorder, Treatment, Etc.

Other

3/2/19

Quick Sorting of "Risk Assessment" Tools

- Questions you should ask yourself when you reexamine the "risk assessment" process and tools you use:
 - Which Risk Domain am I Addressing with a Particular Process or Tool?
 - How often do I use the tool? What should I do if I used the tool too often and the patient has given different answers?
 - How will I document that I addressed the same?
 - How will I factor the patient's "risk" under that domain into my overall risk evaluation of him/her?
 - How will I do so without inappropriately labeling the patient?
 - Do I need outside peer support to properly evaluate the patient?
 - How will I structure my "risk levels" –
 - Low, moderate, high?
 - Low and Mod/high?
 - Low and High?
 - How will I establish my treatment plan boundaries for each risk level? How will I keep this information current, so I can see it before each visit or procedure?

3/2/19



3/28/19

A Quick Glance at a Couple of Tools Focused on Abuse, Misuse, Diversion, Opioid Use Disorders

Read the fine print

Opioid Risk Tool (ORT)

- Background
- What "risk" does it assess?
- How does it "rank" risk?
- How should that factor into the "rest of the story"?

3/28/19

Opioid Risk Tool

Introduction

The Opioid Risk Tool (ORT) is a brief, self-report screening tool designed for use with adult patients in primary care settings to assess risk for opioid abuse among individuals prescribed opioids for treatment of chronic pain. Patients categorized as high-risk are at increased likelihood of future abusive drug-related behavior. The ORT can be administered and scored in less than 1 minute and has been validated in both male and female patients, but not in non-pain populations.

BIG HINT . . .

- DO, NOT,
- GIVE THE QUESTIONNAIRE WITH THE SCORING INFORMATION,
- TO, THE, PATIENT.

3/28/19

Opioid Risk Tool

This tool should be administered to patients upon an initial visit prior to beginning opioid therapy for pain management. A score of 3 or lower indicates low risk for future opioid abuse, a score of 4-5 indicates moderate risk for opioid abuse, and a score of 6 or higher indicates a high risk for opioid abuse.

Mark each box that applies	Female	Male
Family history of substance abuse		
Alcohol	1	3
Illegal drugs	2	3
The Opioid	4	4
Personal history of substance abuse		
Alcohol	3	3
Illegal drugs	4	4
The Opioid	5	5
Age between 18-45 years	1	1
History of psychiatric or mental illness		
Psychological disease	2	2
ADD, OCD, bipolar, schizophrenia	2	2
Depression	2	1
Scoring levels		

General Resources for Tools on Medication and Medical Risks: Evaluation and Monitoring

CDC

SAMHSA (focus for purpose of lecture)

FSMB

State Licensing Boards

Local Medical Associations


3/2/19

SAMHSA Opioid Overdose TOOLKIT: Information for Prescribers

3/2/19

SAMHSA Original Toolkit and Link to 2016 Kit

<https://store.samhsa.gov/product/Opioid-Overdose-Prevention-Toolkit-Updated-2016/All-New-Products/SMA16-474>



OPPIOID OVERDOSE

3/2/19

CONSIDER PRESCRIBING NALOXONE ALONG WITH THE PATIENT'S INITIAL OPIOID PRESCRIPTION. Naloxone competitively binds opioid receptors and is the antidote to acute opioid toxicity. It will rapidly eliminate symptoms of opioid toxicity and allow the patient to breathe normally.

Recent therapy and other at-risk factors may include:

- Taking high doses of opioids for long-term management of chronic (persistent) or acute (intermittent) pain
- Receiving intrathecal opioid medication regimens (such as an epidural for postoperative pain management)
- Discharged from emergency medical care following opioid intoxication or poisoning
- At high risk for overdose because of a high-risk medical record for overdose, combined with a non-patient or confirmed history of substance abuse, dependence, or non-medical use of prescription or over-the-counter drugs
- On certain opioid preparations that may increase risk for opioid overdose such as extended-release, long-acting opioid preparations
- Combining benzodiazepine, sedation/analgesia, or alcoholism programs


Patients who are candidates for such kits include those who are:

- In the past 6 months, have you taken any medications to help you calm down, keep from getting nervous or "chill" when your system, such as beta-blockers, anti-depressants?
- Have you been taking alcohol for the past 6 months?
- Have you ever taken a prescription to help you with a drug or alcohol problem?
- Have you ever taken a medication for a nervous condition?
- Have you taken a medication to give you more energy or to cut down on your appetite?
- Have you ever been treated for a possible or suspected opioid overdose?

SAMHSA Opioid Overdose Toolkit

SAMHSA
Medication
List

3/3/19



Resources: Websites


CDC
<http://www.cdc.gov/drugoverdose/prescribing/providers.htm>
 • Provider and patient materials, including prescribing checklists, flyers, and posters

SAMHSA
<http://www.samhsa.gov/atod/opioids>

DHMH Opioid Website
dhhm.maryland.gov/medicaid-opioid-dur

DEPARTMENT OF HEALTH & HUMAN SERVICES

3/3/19



A FEW CASE EXAMPLES OF
MISSED OPPORTUNITIES IN RISK
EVALUATION/MONITORING


3/2/19



Explain how to create a risk evaluation action plan and supporting documentation.


Objective 3

3/28/19



Key is TIMELY Assessment and Evaluation for use in treatment of patient and Physician Involvement

3/28/19



**Legal Perspective:
Critical Risk
Monitoring
Considerations**

- Frequency of visit AND Frequency of re-evaluation with MD
- Frequency of PDMP check if state does not require specific frequency
- Frequency of Drug Testing and Nature of Drug Testing Menu
- Type of medications that will be allowed
- Dose and Combination of medications that will be allowed without additional monitoring and provider support, including consults/referrals
- Issuance and Confirmation of Naloxone Prescription
- Exit or Additional Provider Support Strategies

3/28/19

PHYSICIAN DIRECT INVOLVEMENT IN PATIENT RISK MONITORING


How often does the MD see the patient?

- Initial visit?
- Thereafter?

How often should the MD see the patient?

- Relative to patient risk level?
- Relative to patient progress/lack thereof with Tx plan?
- Both?

3/2/19



Naloxone and Minimizing Risk | Quick Reminder


3/2/19

REMEMBER:

It does not do any good to issue a Naloxone prescription to a high risk patient without making sure they filled it.

Some states may provide a limited immunity here; Most do not.

3/2/19



Education: It's a Process
and Not a One-Time Thing

Parents and Staff

3/28/19


EDUCATE PATIENTS (and HIPAA-Consented Family/Friends) FROM THE START

SAFE USE

SAFE STORAGE

SAFE DISPOSAL


NALOXONE



3/28/19

Adjust your Written Treatment Agreement

- Patient's agreement **NOT TO ABUSE ALCOHOL**
 - Test for it
 - Deal with it relative to ongoing opioid therapy (or B2O therapy)
- Patient's agreement **TO NOT USE OTHER MEDICALLY UNAUTHORIZED SUBSTANCES** (including THC)
 - Test for THC
 - Deal with it relative to ongoing opioid therapy (or B2O therapy)




3/28/19

Coordination of Care
Addressing the Weaknesses




3/2/19

CONSULTATION & COORDINATION OF CARE



3/2/19



Addressing Adverse Patient Events in a Timely Fashion

With your staff
In your practice processes and work flows
In your documentation practices


3/2/19

REMINDER

Individualized Patient Care:

1. Looks backwards and constantly reevaluates the data points
2. And moves forward with the patient's best interests in mind, carefully balancing risks and benefits

3/28/19



Questions?

- Thank you!
- **Jennifer Bolen, JD**
- 865-755-2369
- jbolen@legalsideofpain.com

3/28/19
